MCQ Quiz: Assessment & Management of Chronic Pain

Chronic pain is a complex disease state that persists beyond normal healing time, profoundly impacting a patient’s function and quality of life. Its management, a key topic in the Patient Care 3 curriculum “, shifts the focus from simply reducing pain intensity to improving daily function and requires a multimodal approach. This quiz will test your knowledge on the assessment of chronic pain, the role of non-pharmacologic therapies, and the evidence-based use of non-opioid, adjuvant, and opioid analgesics.

1. Chronic pain is best defined as pain that persists or recurs for longer than:

  • a. 24 hours
  • b. 1 week
  • c. 1 month
  • d. 3-6 months

Answer: d. 3-6 months

2. The primary goal of chronic pain management is:

  • a. To completely eliminate all pain sensation (a pain score of 0/10).
  • b. To improve function and quality of life, even if some pain persists.
  • c. To find the highest tolerable dose of an opioid.
  • d. To ensure the patient receives a disability diagnosis.

Answer: b. To improve function and quality of life, even if some pain persists.

3. A patient describes their chronic pain as “burning, shooting, and electrical.” This is characteristic of what type of pain?

  • a. Nociceptive somatic pain
  • b. Nociceptive visceral pain
  • c. Neuropathic pain
  • d. Acute pain

Answer: c. Neuropathic pain

4. Which of the following is considered a first-line pharmacologic treatment for neuropathic pain?

  • a. A strong opioid like fentanyl.
  • b. An NSAID like naproxen.
  • c. An antidepressant like duloxetine or a gabapentinoid like pregabalin.
  • d. Acetaminophen.

Answer: c. An antidepressant like duloxetine or a gabapentinoid like pregabalin.

5. The “4 A’s” of monitoring a patient on chronic opioid therapy include Analgesia, Activity, Adverse effects, and:

  • a. Adherence
  • b. Aberrant drug-related behaviors
  • c. Addiction
  • d. Allergies

Answer: b. Aberrant drug-related behaviors

6. The “Pharmacotherapy of Pain” is a specific lecture in which course?

  • a. PHA5878C Patient Care 3
  • b. PHA5104 Sterile Compounding
  • c. PHA5703 Pharmacy Law and Ethics
  • d. PHA5787C Patient Care 5

Answer: a. PHA5878C Patient Care 3

7. Which non-opioid medication is considered a reasonable first-line option for mild-to-moderate chronic osteoarthritis pain?

  • a. Ibuprofen
  • b. Acetaminophen
  • c. Celecoxib
  • d. Tramadol

Answer: b. Acetaminophen

8. “Multimodal analgesia” in chronic pain refers to:

  • a. Using only opioid medications.
  • b. Using only non-pharmacologic therapies.
  • c. Combining different pharmacologic and non-pharmacologic strategies to target pain through multiple mechanisms.
  • d. Using only adjuvant analgesics.

Answer: c. Combining different pharmacologic and non-pharmacologic strategies to target pain through multiple mechanisms.

9. Which of the following is a key non-pharmacologic treatment for chronic pain?

  • a. Complete bed rest and inactivity.
  • b. Physical therapy and graded exercise.
  • c. A diet high in inflammatory foods.
  • d. Daily use of a heating pad only.

Answer: b. Physical therapy and graded exercise.

10. A patient on chronic opioid therapy develops tolerance. This means:

  • a. They are addicted to the medication.
  • b. They require a higher dose of the opioid to achieve the same level of pain relief.
  • c. They are experiencing withdrawal symptoms.
  • d. They are diverting their medication.

Answer: b. They require a higher dose of the opioid to achieve the same level of a pain relief.

11. The “Introduction to Pain and Treatment Options” is a module within the Patient Care 3 curriculum.

  • a. True
  • b. False

Answer: a. True

12. Amitriptyline is a tricyclic antidepressant used for neuropathic pain. Its use is often limited by:

  • a. Its high cost.
  • b. Its anticholinergic side effects.
  • c. Its lack of efficacy.
  • d. Its need for IV administration.

Answer: b. Its anticholinergic side effects.

13. A patient on chronic opioid therapy should always be co-prescribed what medication?

  • a. An antiemetic
  • b. A prophylactic bowel regimen (e.g., a stimulant laxative)
  • c. An anxiolytic
  • d. An antidepressant

Answer: b. A prophylactic bowel regimen (e.g., a stimulant laxative)

14. A state’s Prescription Drug Monitoring Program (PDMP) is a tool pharmacists should use when dispensing opioids to:

  • a. Check for overlapping prescriptions from multiple prescribers.
  • b. Assess for potential diversion or misuse.
  • c. Verify the patient’s controlled substance history.
  • d. All of the above.

Answer: d. All of the above.

15. Counseling patients on self-care for pain is a key objective for student pharmacists.

  • a. True
  • b. False

Answer: a. True

16. The primary goal of assessing chronic pain should be focused on:

  • a. The pain score only.
  • b. The patient’s mood only.
  • c. The impact of pain on the patient’s physical and social function.
  • d. The patient’s opioid tolerance.

Answer: c. The impact of pain on the patient’s physical and social function.

17. The “Self-Care for Pain and Fever” lecture is part of the Patient Care 3 curriculum.

  • a. True
  • b. False

Answer: a. True

18. Which of the following is a key difference in the management of acute versus chronic pain?

  • a. Opioids are first-line for all types of chronic pain.
  • b. The goals shift from simple pain relief to improved function and quality of life in chronic pain.
  • c. Non-pharmacologic therapy has no role in chronic pain.
  • d. Chronic pain is easier to treat than acute pain.

Answer: b. The goals shift from simple pain relief to improved function and quality of life in chronic pain.

19. A topical lidocaine patch is most effective for what type of pain?

  • a. Deep visceral pain
  • b. Diffuse, widespread neuropathic pain.
  • c. Localized neuropathic pain, such as postherpetic neuralgia.
  • d. Acute surgical pain.

Answer: c. Localized neuropathic pain, such as postherpetic neuralgia.

20. An active learning session on pain management is part of the Patient Care 3 course.

  • a. True
  • b. False

Answer: a. True

21. “Physical dependence” on an opioid means:

  • a. The patient is addicted.
  • b. The patient will experience withdrawal symptoms if the opioid is abruptly stopped.
  • c. The patient is using the drug for non-medical reasons.
  • d. The drug is no longer effective.

Answer: b. The patient will experience withdrawal symptoms if the opioid is abruptly stopped.

22. Which of the following is an example of an SNRI used for chronic pain?

  • a. Fluoxetine
  • b. Sertraline
  • c. Duloxetine
  • d. Citalopram

Answer: c. Duloxetine

23. The “Pharmacology of Analgesics” is a lecture within the Patient Care 3 curriculum.

  • a. True
  • b. False

Answer: a. True

24. An active learning session on pain is part of which course?

  • a. PHA5878C Patient Care 3
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient Care 2

Answer: a. PHA5878C Patient Care 3

25. A pharmacist’s role in chronic pain management includes:

  • a. Screening for risk factors for opioid misuse.
  • b. Counseling on the safe storage and disposal of opioids.
  • c. Recommending appropriate adjuvant analgesics.
  • d. All of the above.

Answer: d. All of the above.

26. The use of long-acting opioids is generally reserved for:

  • a. All patients with chronic pain.
  • b. Opioid-naïve patients.
  • c. Patients with persistent, moderate-to-severe pain who have demonstrated opioid tolerance.
  • d. The treatment of acute pain only.

Answer: c. Patients with persistent, moderate-to-severe pain who have demonstrated opioid tolerance.

27. What is a key principle when tapering a patient off of chronic opioid therapy?

  • a. The taper should be done as quickly as possible.
  • b. The taper should be slow and individualized to minimize withdrawal symptoms.
  • c. The patient should not be involved in the tapering plan.
  • d. All patients can be tapered off in one week.

Answer: b. The taper should be slow and individualized to minimize withdrawal symptoms.

28. An active learning session on pain is part of which course module?

  • a. Module 1: Introduction to Pain and Treatment Options
  • b. Module 3: Dyslipidemia
  • c. Module 5: Acute Coronary Syndrome
  • d. Module 8: Introduction to Pulmonary Disease

Answer: a. Module 1: Introduction to Pain and Treatment Options

29. The term “analgesic ceiling” means:

  • a. Higher doses of the drug will continue to provide additional pain relief indefinitely.
  • b. A point at which higher doses of a drug do not provide additional pain relief.
  • c. The maximum legal dose of a medication.
  • d. A side effect of an opioid.

Answer: b. A point at which higher doses of a drug do not provide additional pain relief.

30. The “Pharmacotherapy of Pain” is a lecture within the Patient Care 3 curriculum.

  • a. True
  • b. False

Answer: a. True

31. Which class of non-opioid analgesics has an “analgesic ceiling”?

  • a. Opioids
  • b. NSAIDs and acetaminophen
  • c. Gabapentinoids
  • d. None of the above

Answer: b. NSAIDs and acetaminophen

32. The primary goal of a “pain contract” or treatment agreement for chronic opioid therapy is to:

  • a. Create a legal document to protect the prescriber.
  • b. Establish clear expectations and responsibilities for both the patient and the prescriber.
  • c. Punish the patient for any violation.
  • d. Guarantee that the patient will not become addicted.

Answer: b. Establish clear expectations and responsibilities for both the patient and the prescriber.

33. Cognitive Behavioral Therapy (CBT) for chronic pain helps patients by:

  • a. Curing the underlying cause of the pain.
  • b. Changing negative thought patterns and behaviors related to their pain.
  • c. Providing a physical intervention.
  • d. Blocking pain signals in the spinal cord.

Answer: b. Changing negative thought patterns and behaviors related to their pain.

34. Pain management is considered a key topic in which course?

  • a. PHA5878C Patient Care 3
  • b. PHA5784C Patient Care 4
  • c. PHA5787C Patient Care 5
  • d. PHA5781 Patient Care I

Answer: a. PHA5878C Patient Care 3

35. A patient on chronic opioid therapy should be co-prescribed what medication for overdose prevention?

  • a. A benzodiazepine
  • b. An additional opioid
  • c. Naloxone
  • d. An NSAID

Answer: c. Naloxone

36. A key part of the initial assessment for chronic pain is:

  • a. Immediately prescribing a long-acting opioid.
  • b. A thorough patient history, including previous treatments and their efficacy.
  • c. Ordering an MRI for every patient.
  • d. Focusing only on the physical aspect of the pain.

Answer: b. A thorough patient history, including previous treatments and their efficacy.

37. Chronic pain is best managed by:

  • a. A single provider.
  • b. The patient alone.
  • c. A multidisciplinary team including physicians, pharmacists, physical therapists, and psychologists.
  • d. A surgeon only.

Answer: c. A multidisciplinary team including physicians, pharmacists, physical therapists, and psychologists.

38. The Pain & Fever Self-Care module is part of the Patient Care I course.

  • a. True
  • b. False

Answer: a. True

39. Opioid-induced hyperalgesia is a phenomenon where:

  • a. A patient becomes more sensitive to pain as a paradoxical effect of long-term opioid use.
  • b. A patient develops tolerance to the analgesic effects.
  • c. A patient experiences severe constipation.
  • d. A patient has an allergic reaction to an opioid.

Answer: a. A patient becomes more sensitive to pain as a paradoxical effect of long-term opioid use.

40. An active learning session covering pain management is part of which course?

  • a. PHA5878C Patient Care 3
  • b. PHA5163L Professional Skills Lab 3
  • c. PHA5781 Patient Care I
  • d. PHA5782C Patient Care 2

Answer: a. PHA5878C Patient Care 3

41. Which of the following is NOT a first-line agent for fibromyalgia?

  • a. Duloxetine
  • b. Pregabalin
  • c. Amitriptyline
  • d. Oxycodone

Answer: d. Oxycodone

42. The most important component of managing chronic pain is:

  • a. The specific medication prescribed.
  • b. A strong, trusting therapeutic relationship between the patient and the healthcare team.
  • c. The use of the newest available technology.
  • d. Regular imaging studies.

Answer: b. A strong, trusting therapeutic relationship between the patient and the healthcare team.

43. A pharmacist’s role in chronic pain management includes all of the following EXCEPT:

  • a. Assessing for aberrant drug-related behaviors.
  • b. Counseling on the risks of long-term opioid use.
  • c. Performing interventional pain procedures like nerve blocks.
  • d. Recommending non-pharmacologic therapies.

Answer: c. Performing interventional pain procedures like nerve blocks.

44. Urine drug testing in a chronic pain clinic is used to:

  • a. Monitor for adherence to prescribed opioids.
  • b. Screen for the use of non-prescribed or illicit substances.
  • c. Both a and b.
  • d. Punish the patient.

Answer: c. Both a and b.

45. Which of the following is a central principle of chronic pain management?

  • a. The goal is a quick fix.
  • b. The focus is on active patient participation and self-management strategies.
  • c. The patient is a passive recipient of care.
  • d. Pharmacologic therapy is the only effective treatment.

Answer: b. The focus is on active patient participation and self-management strategies.

46. “Defending a therapeutic plan” for a pain patient is an objective in the skills lab curriculum.

  • a. True
  • b. False

Answer: a. True

47. The laws regarding the prescribing of controlled substances are a key part of which course?

  • a. PHA5703 Principles of Pharmacy Law and Ethics
  • b. PHA5244 Principles of Evidence-Based Practice
  • c. PHA5104 Sterile Compounding
  • d. PHA5176 Drug Delivery Systems

Answer: a. PHA5703 Principles of Pharmacy Law and Ethics

48. An active learning session on pain is part of which course module?

  • a. Module 1: Introduction to Pain and Treatment Options
  • b. Module 2: Hypertension
  • c. Module 4: Ischemic Heart Disease
  • d. Module 7: Arrhythmias

Answer: a. Module 1: Introduction to Pain and Treatment Options

49. The overall management of chronic non-cancer pain should prioritize:

  • a. Opioid therapy above all other treatments.
  • b. Non-opioid and non-pharmacologic therapies.
  • c. Surgical interventions.
  • d. A “wait and see” approach.

Answer: b. Non-opioid and non-pharmacologic therapies.

50. The ultimate goal of learning about chronic pain management is to:

  • a. Be able to safely and compassionately help patients manage their condition to improve their overall quality of life and function.
  • b. Become an expert at denying opioid prescriptions.
  • c. Pass the final exam.
  • d. Memorize all the different types of pain scales.

Answer: a. Be able to safely and compassionately help patients manage their condition to improve their overall quality of life and function.

Author

  • G S Sachin
    : Author

    G S Sachin is a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. He holds a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research and creates clear, accurate educational content on pharmacology, drug mechanisms of action, pharmacist learning, and GPAT exam preparation.

    Mail- Sachin@pharmacyfreak.com

Leave a Comment

PRO
Ad-Free Access
$3.99 / month
  • No Interruptions
  • Faster Page Loads
  • Support Content Creators